Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.